Xiaobo Wang

Xiaobo Wang currently serves as the Lead Principal Scientist at Otonomy, Inc., a position held since October 2008, where significant contributions to multiple hearing loss programs include AAV gene therapy for genetic hearing loss, otoprotection for cisplatin-induced hearing loss, and hair cell regeneration for severe hearing loss. This role involves leadership in GLP studies, innovative dosing methods, and comprehensive efficacy, pharmacokinetics, pharmacodynamics, and toxicity research. Previously held positions include Principal Scientist at Otonomy, Inc., Director of Pharmacology at Corti Therapeutics, and Associate Researcher III at the University of California, San Diego, focusing on autoimmune inner ear disorders. Xiaobo Wang's educational background includes a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Shandong Medical University.